iSpecimen announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $5.5M, before deducting fees to the placement agent and other offering expenses payable by the company. In connection with the offering, the company will issue 6,875 shares of newly designated Series C convertible preferred stock at a price of $800 per share. Each share of preferred stock is convertible into shares of the company's common stock based on a $1,000 stated value per preferred stock share and a conversion price of 85% of the closing price of the common stock as of the date prior to each conversion date. The company intends to use the net proceeds from the offering for marketing, working capital, and general corporate purposes. The offering is expected to close on or about December 31, subject to the satisfaction of customary closing conditions. E.F. Hutton & Co. is acting as the exclusive placement agent in connection with the offering.
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.